A review of nicotinamide: Treatment of skin diseases and potential side effects

Journal of Cosmetic Dermatology

Volumn 13, Issue 4, 2014, Pages 324-328

  Rolfe, Heidi M ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Acne vulgaris; Dermatitis; Melasma; Niacinamide; Nicotinamide; Rosacea; Skin cancer; Vitamin B3

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; COPPER; FOLIC ACID; HYDROQUINONE; INSULIN; METHOTREXATE; N METHYLNICOTINAMIDE; NICOTINAMIDE; NICOTINIC ACID; PLACEBO; ZINC; VITAMIN B COMPLEX;

ACNE; ACNE VULGARIS; ACTINIC KERATOSIS; ATOPIC DERMATITIS; BREAST FEEDING; BURNING SENSATION; CANCER PATIENT; CARCINOGENICITY; CHLOASMA; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; ERYTHEMA; HUMAN; INSULIN SENSITIVITY; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; NON MELANOMA SKIN CANCER; NONHUMAN; PARKINSON DISEASE; PREGNANCY; PRURITUS; REVIEW; ROSACEA; SEBUM SECRETION; SKIN DISEASE; ULTRAVIOLET RADIATION; WOUND HEALING; CHEMICALLY INDUCED; DERMATITIS, ATOPIC; DRUG-INDUCED LIVER INJURY; FEMALE; FETOMATERNAL TRANSFUSION; INTRADERMAL DRUG ADMINISTRATION; MELANOSIS; ORAL DRUG ADMINISTRATION; SKIN DISEASES; SKIN NEOPLASMS;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; DERMATITIS, ATOPIC; DIABETES MELLITUS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; MELANOSIS; NIACINAMIDE; PARKINSON DISEASE, SECONDARY; PREGNANCY; ROSACEA; SKIN DISEASES; SKIN NEOPLASMS; VITAMIN B COMPLEX;

EID: 84912116814     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/jocd.12119     Document Type: Review

References (37)

1. Zhou S-S, Li D, Sun W-P et al. Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol 2009; 15: 5674-84.
2. Williams A, Ramsden D. Nicotinamide: a double edged sword. Parkinsonism Relat Disord 2005; 11: 413-20.
3. Gehring W. Nicotinic acid/niacinamide and the skin. J Cosmet Dermatol 2004; 3: 88-93.
4. Kademian M, Bechtel M, Zirwas M. Case reports: new onset flushing due to unauthorized substitution of niacin for nicotinamide. J Drugs Dermatol 2007; 6: 1220-1.
5. Kim NH, Kirsner RS. Nicotinamide in Dermatology. Expert Rev Dermatol 2010; 5: 23-9.
6. Jacobson EL, Shieh WM, Huang AC. Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. Mol Cell Biol 1999; 193: 69-74.
7. Comaish JS, Felix RH, McGrath H. Topically applied niacinamide in isoniazid-induced pellagra. Arch Dermatol 1976; 112: 70-2.
8. Knip M, Douck IF, Moore WPT et al. Safety of high dose nicotinamide: a review. Diabetologia 2000; 43: 1337-45.
9. Draelos ZD, Matsubara A, Smiles KJ. The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther 2006; 8: 96-101.
10. Kaymak Y, Onder M. An investigation of efficacy of topical niacinamide for the treatment of mild and moderate acne vulgaris. J Turk Acad Dermatol 2008; 2: jtad82402a.
11. Shalita AR, Smith JG, Parish LC et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 1995; 34: 434-7.
12. Collins TM, Caimi R, Lynch PR et al. The effects of nicotinamide and hyperbaric oxygen on skin flap survival. Scand J Plast Reconstr Surg Hand Surg 1991; 25: 5-7.
13. Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B et al. A Double-Blind Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the treatment of Melasma. Dermatol Res Pract 2011; 2011: 379173.
14. Hakozaki T, Minwalla J, Zhuang J et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002; 147: 20-31.
15. Soma Y, Kashima M, Imaizumi A et al. Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol 2005; 44: 197-202.
16. Tanno O, Ota Y, Kitamura N et al. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol 2000; 143: 524-31.
17. Wozniacka A, Wieczorkowska M, Gebicki J et al. Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin Exp Dermatol 2005; 30: 632-5.
18. Wozniacka A, Sysa-Jedrzejowska A, Adamus J et al. Topical application of NADH for the treatment of rosacea and contact dermatitis. Clin Exp Dermatol 2003; 28: 61-3.
19. Bissett DL, Oblong JE, Saud A et al. Topical niacinamide provides skin aging appearance benefits while enhancing barrier function. J Clin Dermatol 2003; 32: S9-1.
20. Streilein JW, Taylor JR, Vincek V et al. Relationship between ultraviolet radiation-induced immunosuppression and carcinogenesis. J Invest Dermatol 1994; 103: 107S-11S.
21. Gerlini G, Romagnoli P, Pimpinelli N. Skin cancer and immunosuppression. Crit Rev Oncol Hematol 2005; 56: 127-36.
22. Freiman A, Bird G, Metelista AI et al. Cutaneous effects of smoking. J Cutan Med Surg 2004; 8: 415-23.
23. Damian DL, Patterson CRS, Stapelberg M et al. UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol 2008; 128: 447-54.
24. Rovito HA, Oblong JE. Nicotinamide preferentially protects glycolysis in dermal fibroblasts under oxidative stress conditions. Br J Dermatol 2013; 169: 15-24.
25. Monfrecola G, Gaudiello F, Cirillo T et al. Nicotinamide down regulates gene expression of interleukin-6, interleukin-10, monocyte chemoattractant protein-1, and tumour necrosis factor-α gene expression in HaCaT keratinocytes after ultraviolet B irradiation. Clin Exp Dermatol 2013; 38: 185-8.
26. Surjana D, Halliday G, Martin AJ et al. Oral nicotinamide reduces actinic keratoses in phase ii double-blinded randomized controlled trials. J Invest Dermatol 2012; 132: 1497-500.
27. Niren NM, Torok HM. The Nicomide Improvement in Clinical Outcomes Study (NICOS): results of an 8-week trial. Cutis 2006; 77: 17-28.
28. Fukushima T. Niacin metabolism and Parkinson's disease. Environ Health Prev Med 2005; 10: 3-8.
29. Okada K, Matsubara K, Kobayashi S et al. Abnormal N-methylation of nicotinamide in Parkinson's disease. Neurobiol Aging 1996; 1: S69.
30. Green S, Buttrum S, Molloy H et al. N-methylation of pyridines in Parkinson's disease: nicotinamide loading test. J Neural Transm 2000; 107: 985-95.
31. Gale EA, Bigley PJ, Emett CL et al. European Nicotinamide Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925-31.
32. Elliott RB, Pilcher CC, Fergusson DM et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996; 9: 501-9.
33. Handler P, Dann WJ. The inhibition of rat growth by nicotinamide. J Biol Chem 1942; 146: 357-8.
34. Elliot RB, Pilcher CC, Stewart A et al. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci 1993; 696: 333-41.
35. Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med 1973; 289: 1180-2.
36. Namazi MR. Nicotinamide a potential addition to the antipsoriatic weaponry. FASEB J 2003; 17: 1377-9.
37. Stockton DL, Paller AS. Drug administration to the pregnant or lactating woman: a reference guide for dermatologists. J Am Acad Dermatol 1990; 23: 87-103.